Reply to Petricevic et al.

administration revealed significantly lower test values in the group of patients exposed to RBC (P = 0.002) [2]. The role of ASA and CLO administration management should be separately assessed by drug-specific platelet function tests, thus facilitating an individual therapeutic approach for each antiplatelet agent preoperatively. In addition, intraoperative assessment of platelet function and viscoelastic blood clot properties during CPB can reveal a further degree of haemostatic disorder and its relation to bleeding extent as well as transfusion requirements [3]. Preand intraoperative assessment of platelet function and viscoelastic blood clot properties can distinguish the influence of pre-existing, antiplatelet drugs-related and CPB-acquired haemostatic disorders, allowing detection of risk factors and enabling preoperative (procedure timing, risk stratification, antiplatelet therapy discontinuation management) and intraoperative (targeted administration of desmopressin, tranexaminic acid and procoagulant blood components) practice modifications, which may further lead to improvement in transfusion as well as bleeding, and thus clinical outcome. REFERENCES